The new coronavirus pandemic has triggered a surge in demand for drugs for depression and anxiety disorders, according tomedia. In a may 29 paper, the U.S. Food and Drug Administration (FDA) warned of a shortage of sSRI antidepressants to treat depression and anxiety. The shortage is mainly in high-dose drugs, and the FDA estimates that the problem will take 60 days to resolve.
Zoloft is a brand name for antidepressants and is also sold on the market under the generic name sertraline. The drug, which has prescription strengths ranging from 25 mg to 100 mg, is suitable for a variety of mental health problems, including depression, anxiety, panic disorder and obsessive compulsive disorder. The drug is popular in the U.S., and demand for it has increased as many people feel the strain of the new coronary pneumonia pandemic.
On May 29, the FDA issued a drug recommendation. In its recommendations, the agency noted that the strongest doses of hydrochloric acid sherquer tablets are in short supply, but low-dose supplies are still abundant. The document states that 50mg/500 tablets, 100mg/90s and 100mg/500 tablets are currently either limited or out of stock.
However, this shortage does not appear to be due to increased demand, but rather to some supply chain problem associated with the pandemic. FDA documents state that the shortfall is due to the fact that manufacturers are currently unable to meet monthly demand during the new coronary pneumonia pandemic.
The document states that Accord Healthcare is currently unable to obtain the api (API) needed to manufacture the new coronary pneumonia pandemic. The FDA lists all three of the products mentioned above as products that are expected to be out of stock for 60 days, but other details remain unclear.
However, this shortage has not affected every shetlin manufacturer. As of May 29, Aurobindo Pharma was listed as a pharmaceutical company with a “sufficient number” of all strength drugs, but InvaGen Pharmaceuticals was partially classified as “out of stock” and Lupin was in short supply in all dose specifications due to the low availability of the API.